Amgen Initiates Phase 1b/2 Clinical Trial of Blinatumomab Subcutaneous Formulation for B-cell Lymphoblastic Leukemia Combination Therapy
Maximizing Convenience Through Innovative Administration
Amgen's Blincyto (blinatumomab), a leading bispecific antibody therapy, previously required continuous intravenous (IV) infusion for 28 days, leading to prolonged hospital stays and significantly impacting patients' quality of life. This Phase 1b/2 clinical trial (NCT07153796) aims to address these limitations of the IV administration method and significantly improve patient convenience by evaluating the safety and efficacy of a subcutaneous (SC) formulation. If the SC formulation is commercialized, the administration time can be reduced to just a few minutes, offering an innovative alternative that reduces the burden of long hospital stays and healthcare costs for patients. From a clinical perspective, it also minimizes the adverse effects associated with managing expensive infusion pump equipment and inserting IV catheters, making it highly valuable for use in clinical settings.
Customized, Low-Toxicity Combination Therapy for Elderly Patients
This study primarily targets elderly patients aged 60 and older and patients with B-cell acute lymphoblastic leukemia (B-ALL) who are physically frail and unable to tolerate intensive chemotherapy due to compromised immune systems. To minimize toxicity, the researchers have developed a treatment strategy that combines the SC formulation of blinatumomab with a significantly reduced-intensity chemotherapy regimen, Mini-CVD (Cyclophosphamide, Vincristine, Dexamethasone), and methotrexate/cytarabine (MTX/ARA-C). This aims to reduce the physical burden on patients while effectively suppressing cancer cells and maintaining complete remission (CR) for an extended period. This approach has the potential to provide a safe and effective customized combination therapy for elderly leukemia patients.
Global Leukemia Market Competition and Revenue Growth
The global acute lymphoblastic leukemia (ALL) therapeutics market is a large market, valued at approximately USD 4.19 billion in 2025. Blincyto achieved revenues of USD 861 million in 2024 and is projected to reach USD 1.56 billion in 2025, establishing itself as a blockbuster drug. Amgen currently faces intense competition from other powerful drugs targeting CD19 and CD22, such as Besponsa (inotuzumab ozogamicin) from Pfizer and Kymriah from Novartis. The introduction of the SC formulation in this market represents Amgen's strategic move to extend its market dominance through a formulation shift, improve patient compliance, and outpace competitors. Furthermore, it demonstrates an intention to solidify its long-term market leadership by enabling early intervention in patients who are at the measurable residual disease (MRD) stage, a key indicator for monitoring leukemia recurrence.
Clinical Design Aiming to Redefine Standard Treatment
This trial, led by Dr. Elias Jabbour of the M.D. Anderson Cancer Center, a leading global cancer research institution, commenced actual patient enrollment on January 30, 2026. The study is designed as a single-arm, open-label trial, administering the drug directly to the patient group without a control group, to rapidly assess the initial clinical safety and MRD-negative conversion rate of the SC formulation of blinatumomab. The anticipated completion date for the clinical trial is September 30, 2033. If this study is successful, it is expected to provide critical data for the approval of the SC formulation of Blincyto as a new standard of care for leukemia treatment. The results of this trial will demonstrate the versatility of Amgen's immune-oncology platform and fundamentally change the treatment landscape for elderly patients with hematological malignancies.
This Phase 1b/2 clinical trial represents a pivotal turning point for Amgen's Blincyto, a drug with global revenues of USD 1.56 billion, as it seeks to extend its patent life and maximize market dominance by expanding its territory from intravenous to subcutaneous administration. In the global acute lymphoblastic leukemia (ALL) therapeutics market, valued at approximately USD 4.19 billion in 2025, where it competes with powerful drugs such as Besponsa from Pfizer, the introduction of the SC formulation has the potential to provide a significant competitive advantage by leveraging ease of administration. From a researcher's perspective, it is important to confirm the safety and efficacy of a low-intensity chemotherapy regimen (Mini-CVD) in elderly and frail patients who could not tolerate conventional high-intensity chemotherapy, and to demonstrate improved survival rates by increasing the MRD-negative conversion rate. In the short term, the safety and efficacy data obtained from this trial will serve as direct evidence for the FDA approval application for the SC formulation, and in the long term, it will transform the paradigm of hematological malignancy immunotherapy by shifting it towards an outpatient-centered model, significantly reducing hospitalization and healthcare infrastructure costs.
Source: ClinicalTrials.gov (api_ct)